The positive clinical data strengthen icovamenib's profile across both T1D and T2D, but the stock remains binary on future trial outcomes and regulatory milestones. Monitor the BMF-650 weight reduction data in Q3 2026 as a key catalyst for the GLP-1 program.
Price Chart
Executive Summary
Biomea Fusion presented new clinical and translational data for icovamenib at ADA 2026, showing durable HbA1c improvements in type 2 diabetes and preserved C-peptide in type 1 diabetes without immune activation. The company also expanded its Phase I BMF-650 study to test a rapid titration schedule, with initial weight reduction data expected in Q3 2026. These are positive data readouts for a clinical-stage biotech, but no financial figures or guidance were provided.
Key Facts
- Icovamenib showed a 1.8% placebo-adjusted HbA1c reduction at Week 52 in T2D patients on background GLP-1 RA therapy.
- In T1D patients diagnosed <3 years, 200 mg icovamenib increased C-peptide AUC by ~52% at Week 12 vs baseline; at Week 52, C-peptide remained ~7% below baseline vs ~47% annual decline in historical placebo.
- No evidence of systemic immune activation; inflammatory markers stable or reduced through Week 52.
- Phase I BMF-650 study expanded to evaluate rapid one-step titration; initial 28-day weight reduction data expected in Q3 2026.
- Translational data showed icovamenib enhanced GLP-1 expression, promoted myogenic effects in muscle cells, and induced browning/lipolysis in adipocytes.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Clinical-stage biotech with no approved products or revenue; high binary risk on future trial results.
- Icovamenib's C-peptide preservation at Week 52 was only ~7% below baseline, which may not be statistically significant vs placebo without a formal comparison.
- BMF-650 is in early Phase I; weight reduction data are preliminary and may not replicate in larger trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6230 (−25.30%) |
Oct 13, 2026 13d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6230 (−25.30%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6230 (−56.74%) |
Sep 22, 2026 4w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6230 (+56.74%) |
Sep 22, 2026 4w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6230 (+56.74%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6230 (−46.75%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6230 (−45.83%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6230 (−60.57%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6230 (−60.57%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6230 (−59.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers